This is a StreetInsider.com Premium Only Page

(ORPH) – Business Wire

Feb 24, 2022 08:00 AM CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

Feb 14, 2022 08:00 AM CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

Nov 12, 2021 08:00 AM CytRx Comments on Quarterly Results and Recent Strategic Initiatives

Nov 2, 2021 08:00 AM CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C

Aug 24, 2021 08:00 AM CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C

Aug 12, 2021 04:06 PM CytRx Comments on Quarterly Results and Recent Strategic Initiatives

Jul 29, 2021 04:05 PM CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders

Jul 29, 2021 08:00 AM CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022

Jul 16, 2021 08:00 AM CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor

Jul 13, 2021 08:00 AM CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor

Jun 30, 2021 08:00 AM CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C

Jun 18, 2021 04:30 PM CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C

May 13, 2021 08:00 AM CytRx Comments on Quarterly Results and Year-to-Date Progress

May 10, 2021 08:05 AM Open Orphan plc Announces £3m COVID-19 Challenge Virus Manufacturing Contract

May 7, 2021 04:00 PM CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Apr 1, 2021 04:30 PM CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis

Mar 25, 2021 08:00 AM CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress

Mar 8, 2021 08:00 AM CytRx Highlights Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Mar 4, 2021 08:00 AM CytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Feb 17, 2021 09:25 AM Ethics Approval Granted for Open Orphan’s COVID-19 Human Challenge Study Model

Feb 11, 2021 08:00 AM CytRx is Added to the LD Micro Index

Jan 15, 2021 08:00 AM CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients

Dec 31, 2020 02:00 PM CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Dec 22, 2020 08:00 AM CytRx Comments on Proposed Combination of ImmunityBio and NantKwest

Dec 7, 2020 08:00 AM CytRx Announces Orphazyme’s U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Nov 11, 2020 08:00 AM CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C

Oct 27, 2020 08:00 AM CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

Sep 30, 2020 08:00 AM CytRx Issues Statement Regarding Orphazyme’s Global Offering